[
    [
        {
            "time": "2021-07-14",
            "original_text": "华大基因：上半年预计营收超35亿元，“火眼”平台业务转化初具规模",
            "features": {
                "keywords": [
                    "华大基因",
                    "营收",
                    "火眼平台",
                    "业务转化"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因：上半年预计营收超35亿元，“火眼”平台业务转化初具规模",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-14",
            "original_text": "华大基因：2021上半年预计实现营业收入超过35亿元，肿瘤与感染业务进入高速增长与收获期",
            "features": {
                "keywords": [
                    "华大基因",
                    "营业收入",
                    "肿瘤业务",
                    "感染业务",
                    "高速增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因：2021上半年预计实现营业收入超过35亿元，肿瘤与感染业务进入高速增长与收获期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-14",
            "original_text": "华大基因(300676.SZ)上半年归母净利润同比预降27.34%-39.45% 盈利能力下降",
            "features": {
                "keywords": [
                    "华大基因",
                    "归母净利润",
                    "同比下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因(300676.SZ)上半年归母净利润同比预降27.34%-39.45% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-07-14",
            "original_text": "华大基因：预计上半年盈利10亿元-12亿元，同比下降27.34%-39.4 盈利能力下降",
            "features": {
                "keywords": [
                    "华大基因",
                    "盈利",
                    "同比下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因：预计上半年盈利10亿元-12亿元，同比下降27.34%-39.4 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-07-14",
            "original_text": "华大基因：第一期员工持股计划第一个锁定期到期",
            "features": {
                "keywords": [
                    "华大基因",
                    "员工持股计划",
                    "锁定期到期"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因：第一期员工持股计划第一个锁定期到期",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-07-14",
            "original_text": "华大基因：预计上半年净利润10亿元-12亿元，同比下降27.34%-39.45% 盈利能力下降",
            "features": {
                "keywords": [
                    "华大基因",
                    "净利润",
                    "同比下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因：预计上半年净利润10亿元-12亿元，同比下降27.34%-39.45% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]